Kangzhi Pharmaceutical (300086.SZ) announced its first-half results, with a net loss of 32.765 million yuan to the mother

According to the Zhitong Finance App, Kangzhi Pharmaceutical (300086.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved revenue of 145 million yuan, a year-on-year decrease of 37.67%. The net loss attributable to shareholders of the listed company was RMB 32.765 million, and the net loss attributable to shareholders of the listed company after deducting non-recurring profit and loss was RMB 41.4307 million.

During the reporting period, the pharmaceutical sector achieved revenue of 126 million yuan, with a gross profit margin of 60.10%, an increase of 3.48% over the previous year; among them, children's drugs were the core business pillar, achieving revenue of 93.858 million yuan, a gross profit margin of 66.95%, an increase of 4.72% over the previous year, and a stable profit contribution. During the reporting period, the respiratory product pipeline continued to expand. Carboxymethane granules were approved for marketing, strong loquat syrup completed the resumption of production and return to the market; ibuprofen granules were selected for centralized procurement (continued) procurement of drugs, and centralized volume procurement by the National Proprietary Chinese Medicine Procurement Alliance for cold clean-up granules was further broadened.

During the reporting period, sales expenses decreased by 54.32% year on year, and the efficiency of early marketing investment increased significantly. The company deepens the global terminal layout, and continues to improve channel operation efficiency and core product market penetration rate through “Caring for Women's Health Tour” academic tours, strengthening professional promotion at provincial traditional Chinese medicine pharmacovigilance industry salons, and superimposing various sales models such as online and offline integration.